On this page you’ll find the latest news about CATALONIA.HEALTH and the member companies and knowledge stakeholders in the field of health and life sciences.
If you want to receive our news, please sign up for the monthly newsletter on our website or follow us on X and LinkedIn with the hashtag #WeAreCataloniaHealth.
9 December 2024
Almirall is celebrating its 80th anniversary, marking eight decades of commitment to patients, innovation, and healthcare advancement. To commemorate this milestone, the company hosted an institutional event at its R&D centre in Barcelona, Spain. The event brought together health authorities, partners and institutional representatives, including the President of the Generalitat de Catalunya, Salvador Illa, Juan Cruz Cigudosa, Secretary of State for Science, Innovation, and Universities, together with other personalities and representatives, including members of the board of CATALONIA.HEALTH, of which they are members.
9 December 2024
The Barça Innovation Hub (BIHUB) has become a shareholder of Genomcore, a member of CATALONIA.HEALTH. The startup is recognised as a leader in the management of bio-health data for personalised medicine, with a team made up of clinical staff, biologists and highly experienced engineers. In this new venture, the BIHUB enters the company's share capital together with QVIDTVM, a long-term investment company in innovative organisations in the United States and Europe, which is providing a round of 5 million euros in funding.
2 December 2024
The venture capital company Ysios Capital, member of CATALONIA.HEALTH, participates in the Series B financing round of 135 million dollars of its investee company Adcendo.
29 November 2024
The biopharmaceutical company AELIX Therapeutics, member of CATALONIA.HEALTH, has announced that the US biotech company Gilead Sciences, Inc. has acquired the research assets related to its therapeutic HTI vaccine against HIV.
20 November 2024
The technology platform Gate2Brain, member of CATALONIA.HEALTH, has received the Orphan Drug Designation (ODD) from the European Medicines Agency (EMA) for its innovative product, G2B-002.
20 November 2024
The association has launched two internal committees this 2024, the Internal Talent Committee and the Internal Shared Value Committee, two areas on which the members had pointed out the need to work as a necessity in the health sector in Catalonia. Both were launched just before the summer and join the three that have already been active for some time: the Internal Committees on Innovation, Digital and Business Development.
20 November 2024
The biotechnological company ADmit Therapeutics, member of CATALONIA.HEALTH, receives an accreditation from the Accreditation Committee of the College of American Pathologists (CAP), based on results of a recent on-site inspection as part of the CAP’s Accreditation Programs.
18 November 2024
Full house at the Hub Cambra Digital de Barcelona for the last edition of the CEO Council of 2024, with Elisabeth Stampa as a special guest. Mariona Serra, President of CATALONIA.HEALTH, gave the welcome speech at this year's fifth and last edition of these small committee meetings exclusively for CATALONIA.HEALTH members.
13 November 2024
SMARTDIABETES, the consortium led by the start-up SocialDiabetes, a member of CATALONIA.HEALTH, will receive '1.15 million in funding by the end of 2025 from EIT Health.
13 November 2024
The pharmaceutical company Croda Pharma, member of CATALONIA.HEALTH, announces the launch of Super RefinedTM Poloxamer 188, an innovative bioprocessing solution developed to meet the growing demands of biopharmaceutical development.
7 November 2024
Germans Trias i Pujol Research Institute (IGTP), member of CATALONIA.HEALTH, announces the creation of two new spin-offs: Debios Diagnostics and HealthTech Innovations.
7 November 2024
The advanced therapeutics company Integra Therapeutics, member of CATALONIA.HEALTH, and the Lithuanian company Caszyme have announced a license agreement for the use of Cas12I, Caszyme’s innovative nucleoases, to develop safer and more efficient gene and cell therapies.
4 November 2024
The company INBRAIN Neuroelectronics, a member of CATALONIA.HEALTH, announces the closure of a $50 million Series B financing round. The round has been led by imec.xpand with new investors such as EIC Fund, Fond-ICO Next Tech, CDTI-Innvierte and Avançsa.
31 October 2024
Life sciences venture capital company Asabys Partners, member of CATALONIA.HEALTH, announces the investment in the biotech company Agomab Therapeutics in a Series D financing round that reaches $89 million, along with other existing investors, and with Sanofi and Invius, which join as new investors.
28 October 2024
The new compound AOP208, initially developed by Leukos Biotech, a spin-off of the Josep Carreras Leukemia Research Institute, both members of CATALONIA.HEALTH, has been tested for the first time in patients in the SERONCO-1 phase 1 clinical trial, to assess their safety in patients with advanced solid tumors that is being carried out at the UITM-CaixaResearch Molecular Cancer Therapy Research Unit of the Vall de Hebron Institute of Oncology (VHIO).
24 October 2024
The general director and co-founder of the company specialized in visual and cognitive improvement WIVI Vision, member of CATALONIA.HEALTH, Eva García, wins the Dona TIC 2024 Award in the category of entrepreneur.
23 October 2024
Specialists from the health and technology sector have debated the opportunities and challenges that artificial intelligence presents for the health sector as a whole: improving process efficiency and innovation in the industrial and healthcare fields.
17 October 2024
The leading international group in the production of pharmaceutical active ingredients Moehs, member of CATALONIA.HEALTH, has signed an exclusive agreement with EUROAPI to assume the production of Metamizol, the active ingredient of the drug Nolotil, in its facilities in Spain.
16 October 2024
A worldwide leader in specialized diagnostics Werfen, member of CATALONIA. HEALTH, announces the finalization of a partnership agreement with Seegene Inc. Under the agreement, Seegene and Werfen will set up a NewCo in Spain, Werfen-Seegene, upon the conclusion of mandatory government approvals anticipated by the first half of 2025.
16 October 2024
The company dedicated to personalized medicine Inbiomotion, member of CATALONIA.HEALTH, have signed an exclusive agreement to start offering the MAF Test® in Italy.